Brought to you by 
Altitude Life leads eFFECTOR's $40mm Series B round; increased to $56mm
19 Feb 2016
Executive Summary
Altitude Life Science Ventures led a $40mm Series B round for cancer drug developer eFFECTOR Therapeutics Inc., and also joins the company's board. Additional new investors AbbVie Biotech Ventures and BioMed Venture took part, along with returning backers Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Venture Management, Osage University Partners, and Mission Bay Capital. Some of the proceeds will fund Phase I/II trials of eFT508 for solid tumors, and will also support multiple expansion arms for the project in solid tumors and lymphoma.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Altitude Life leads eFFECTOR's $40mm Series B round; increased to $56mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice